An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Name: An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Published: 2021
License: Public Domain

Viracta Therapeutics, Inc. · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

epstein-barr virus associated lymphoma, ebv-positive dlbcl, nos, ebv-related non-hodgkin lymphoma, ebv related ptcl, nos, ebv-related hodgkin lymphoma, ebv-related ptld, ebv-related lymphoproliferative disorder, epstein-barr virus (ebv), ebv-positive lymphomas, ebv-positive t-cell lymphoma, ebv-positive hodgkin lymphoma, ebv-positive diffuse large b-cell lymphoma (dlbcl)

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 1009744
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.